SLC5A2 and heart disorder: In line with the findings of Kosugi et al. and Gamaza-Chulián et al., our analysis also identified significant improvements in LVM, LVMI, and LV GLS following the administration of SGLT2 inhibitors in diabetic patients without significant cardiac disease [33,34].